Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity.

PubWeight™: 3.40‹?› | Rank: Top 1%

🔗 View Article (PMC 4254577)

Published in Cancer Cell on October 16, 2014

Authors

Miranda L Broz1, Mikhail Binnewies1, Bijan Boldajipour1, Amanda E Nelson1, Joshua L Pollack2, David J Erle2, Andrea Barczak2, Michael D Rosenblum3, Adil Daud4, Diane L Barber5, Sebastian Amigorena6, Laura J Van't Veer7, Anne I Sperling8, Denise M Wolf7, Matthew F Krummel9

Author Affiliations

1: Department of Pathology, University of California San Francisco, San Francisco, CA 94143, USA.
2: Lung Biology Center, University of California San Francisco, San Francisco, CA 94143, USA.
3: Department of Dermatology, University of California San Francisco, San Francisco, CA 94143, USA.
4: Melanoma Clinical Research Unit, University of California San Francisco, San Francisco, CA 94143, USA.
5: Department of Cell and Tissue Biology, University of California San Francisco, San Francisco, CA 94143, USA.
6: INSERM U932, Immunity and Cancer, Institut Curie, 75248 Paris Cedex 05, France.
7: Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA 94143, USA.
8: Committee on Immunology, University of Chicago, 924 E. 57th Street, Chicago, IL 60637, USA.
9: Department of Pathology, University of California San Francisco, San Francisco, CA 94143, USA. Electronic address: matthew.krummel@ucsf.edu.

Associated clinical trials:

Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors (INTRUST) | NCT03792724

Articles citing this

Visualization of immediate immune responses to pioneer metastatic cells in the lung. Nature (2016) 2.33

Immune cell promotion of metastasis. Nat Rev Immunol (2015) 2.15

Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell (2015) 2.10

Regulatory T Cells in Skin Facilitate Epithelial Stem Cell Differentiation. Cell (2017) 2.03

Macrophages and therapeutic resistance in cancer. Cancer Cell (2015) 1.95

Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. Immunity (2016) 1.69

The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell (2015) 1.66

Type I interferons in anticancer immunity. Nat Rev Immunol (2015) 1.57

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med (2016) 1.52

Adaptive Immune Regulation of Mammary Postnatal Organogenesis. Dev Cell (2015) 1.48

Systemic Immunity Is Required for Effective Cancer Immunotherapy. Cell (2017) 1.44

Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell (2017) 1.40

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature (2017) 1.39

Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest (2015) 1.24

T cell migration, search strategies and mechanisms. Nat Rev Immunol (2016) 1.16

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity (2016) 1.11

Immune suppressive mechanisms in the tumor microenvironment. Curr Opin Immunol (2015) 1.02

Transcriptional Control of Dendritic Cell Development. Annu Rev Immunol (2015) 0.97

Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. Int Immunol (2016) 0.94

XCR1+ dendritic cells promote memory CD8+ T cell recall upon secondary infections with Listeria monocytogenes or certain viruses. J Exp Med (2015) 0.93

The role of myeloid cells in cancer therapies. Nat Rev Cancer (2016) 0.92

Functional Specialization of Skin Dendritic Cell Subsets in Regulating T Cell Responses. Front Immunol (2015) 0.92

Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. Cancer Cell (2016) 0.91

Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models. Front Immunol (2015) 0.91

Investigating Evolutionary Conservation of Dendritic Cell Subset Identity and Functions. Front Immunol (2015) 0.91

Targeting microRNAs as key modulators of tumor immune response. J Exp Clin Cancer Res (2016) 0.89

Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells. Cancer Discov (2015) 0.88

Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies. Clin Cancer Res (2016) 0.87

Mouse models in oncoimmunology. Nat Rev Cancer (2016) 0.85

STAT3 Establishes an Immunosuppressive Microenvironment during the Early Stages of Breast Carcinogenesis to Promote Tumor Growth and Metastasis. Cancer Res (2015) 0.85

Cancer-Associated Myeloid Regulatory Cells. Front Immunol (2016) 0.85

CD103+ dendritic cells producing interleukin-12 in anticancer immunosurveillance. Cancer Cell (2014) 0.84

Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. Immunotherapy (2015) 0.83

Biphasic function of TLR3 adjuvant on tumor and spleen dendritic cells promotes tumor T cell infiltration and regression in a vaccine therapy. Oncoimmunology (2016) 0.81

Fate mapping of dendritic cells. Front Immunol (2015) 0.81

Dendritic Cells and Cancer Immunity. Trends Immunol (2016) 0.80

The emerging understanding of myeloid cells as partners and targets in tumor rejection. Cancer Immunol Res (2015) 0.79

Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells. Sci Immunol (2017) 0.78

Targeting CLEC9A delivers antigen to human CD141(+) DC for CD4(+) and CD8(+)T cell recognition. JCI Insight (2016) 0.78

Myeloid Cells as Targets for Therapy in Solid Tumors. Cancer J (2015) 0.78

Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. Front Immunol (2015) 0.78

Until Death Do Us Part: Necrosis and Oxidation Promote the Tumor Microenvironment. Transfus Med Hemother (2016) 0.78

The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity. Nat Commun (2016) 0.78

The transcriptome of lung tumor-infiltrating dendritic cells reveals a tumor-supporting phenotype and a microRNA signature with negative impact on clinical outcome. Oncoimmunology (2016) 0.78

Tumor-infiltrating lymphocytes are dynamically desensitized to antigen but are maintained by homeostatic cytokine. JCI Insight (2016) 0.78

An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nat Commun (2016) 0.78

Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol Med (2016) 0.77

Functions of Murine Dendritic Cells. Immunity (2016) 0.77

Live cell imaging to understand monocyte, macrophage, and dendritic cell function in atherosclerosis. J Exp Med (2016) 0.77

Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines. J Immunol Res (2015) 0.77

Ontogeny of Tumor-associated Macrophages and Its Implication in Cancer Regulation. Trends Cancer (2016) 0.77

TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. Immunol Rev (2017) 0.77

Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells. Sci Signal (2016) 0.77

Intratumoral dendritic cells in the anti-tumor immune response. Cell Mol Immunol (2015) 0.77

Isolation of Mouse and Human Tumor-Associated Macrophages. Adv Exp Med Biol (2016) 0.76

Delineating CSF-1-dependent regulation of myeloid cell diversity in tumors. Oncoimmunology (2015) 0.76

The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol (2017) 0.75

Human Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity. Front Immunol (2017) 0.75

GM-CSF Inhibits c-Kit and SCF Expression by Bone Marrow-Derived Dendritic Cells. Front Immunol (2017) 0.75

Monocyte-Derived Dendritic Cells Are Essential for CD8(+) T Cell Activation and Antitumor Responses After Local Immunotherapy. Front Immunol (2015) 0.75

Microenvironment: the new midfielders in the tumour microenvironment. Nat Rev Cancer (2014) 0.75

Systemic treatment for hepatocellular carcinoma: Still unmet expectations. World J Hepatol (2017) 0.75

Duality at the gate: Skin dendritic cells as mediators of vaccine immunity and tolerance. Hum Vaccin Immunother (2016) 0.75

Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103(+) dendritic cells in late-stage ovarian cancer. Oncoimmunology (2016) 0.75

A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model. Mol Ther Oncolytics (2017) 0.75

Tumour immunology: the new midfielders in the tumour microenvironment. Nat Rev Immunol (2014) 0.75

Phenotypic dynamics of microglial and monocyte-derived cells in glioblastoma-bearing mice. Sci Rep (2016) 0.75

Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours. Sci Rep (2016) 0.75

State-of-the-art of regulatory dendritic cells in cancer. Pharmacol Ther (2016) 0.75

An Immunosuppressive Dendritic Cell Subset Accumulates at Secondary Sites and Promotes Metastasis in Pancreatic Cancer. Cancer Res (2017) 0.75

Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccines. J Leukoc Biol (2017) 0.75

Loss of MAPK-activated protein kinase 2 enables potent dendritic cell-driven anti-tumour T cell response. Sci Rep (2017) 0.75

Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier. Acta Pharmacol Sin (2017) 0.75

The role of dendritic cells in cancer. Semin Immunopathol (2016) 0.75

Immunoplasticity in cutaneous melanoma: beyond pure morphology. Virchows Arch (2017) 0.75

Versican-Derived Matrikines Regulate Batf3-Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal Cancer. J Immunol (2017) 0.75

Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer. J Immunother Cancer (2017) 0.75

Articles cited by this

Hallmarks of cancer: the next generation. Cell (2011) 140.01

Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94

Development of monocytes, macrophages, and dendritic cells. Science (2010) 12.86

The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29

Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A (2005) 10.85

Distinct role of macrophages in different tumor microenvironments. Cancer Res (2006) 9.29

A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science (2012) 8.42

Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science (2008) 7.87

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011) 7.65

A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res (2004) 7.56

Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat Immunol (2012) 7.32

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 6.20

Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol (2001) 6.20

BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol (2000) 6.04

NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell (2006) 5.35

Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas. Cell (2010) 5.28

The origin and development of nonlymphoid tissue CD103+ DCs. J Exp Med (2009) 4.79

Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science (2010) 4.56

Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res (2010) 4.25

Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell (2014) 4.17

Deciphering the transcriptional network of the dendritic cell lineage. Nat Immunol (2012) 4.17

Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells. Immunity (2012) 3.58

Dendritic cell and macrophage heterogeneity in vivo. Immunity (2011) 3.41

Cell-type specific gene expression profiles of leukocytes in human peripheral blood. BMC Genomics (2006) 3.27

Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol (2005) 3.20

IFN regulatory factor-4 and -8 govern dendritic cell subset development and their functional diversity. J Immunol (2005) 3.15

Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage. J Exp Med (2012) 2.51

Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci U S A (2012) 2.42

Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell (2014) 2.40

CD301b⁺ dermal dendritic cells drive T helper 2 cell-mediated immunity. Immunity (2013) 2.31

Compensatory dendritic cell development mediated by BATF-IRF interactions. Nature (2012) 2.25

Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell (2012) 1.95

Control of T helper 2 responses by transcription factor IRF4-dependent dendritic cells. Immunity (2013) 1.88

Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res (2009) 1.77

GM-CSF-based cancer vaccines. Immunol Rev (2002) 1.71

CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8(+) T cells. Oncoimmunology (2013) 1.57

The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors. J Immunol (2001) 1.34

Transcription factor IRF4 drives dendritic cells to promote Th2 differentiation. Nat Commun (2013) 1.29

CD8+ tumor-infiltrating T cells are trapped in the tumor-dendritic cell network. Neoplasia (2013) 1.11

Efficient DNA-mediated transfer of selectable genes and unselected sequences into differentiated and undifferentiated mouse melanoma clones. Somat Cell Mol Genet (1984) 1.10

Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity. PLoS One (2014) 0.90

Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency. Lipids Health Dis (2010) 0.85